Jennifer O. Lauchle
Hematology | Oncology
1635 Divisadero St Ste 625
San Francisco, CA 94115
San Francisco, CA 94115
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 09, 2023
Clinical Translation: Targeting the Estrogen Receptor.
Journal: Advances in experimental medicine and biology
Published: September 15, 2022
Myths about diversity in clinical trials reduce return on investment for industry.
Journal: Nature medicine
Published: June 06, 2022
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 23, 2018
A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
Journal: Cancer research
Published: June 16, 2017
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 14, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Journal: Cancer
Published: March 28, 2016
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Journal: The Journal of clinical investigation
Published: January 05, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 11, 2015
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
Journal: The Journal of clinical investigation
Published: February 01, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026